Abstract:ABSTRACT. Rift Valley fever virus (RVFV) is one of the important emerging viral diseases of serious impact in public health and animal hygiene both in human and animal industries. In this study, we developed a monoclonal antibody-based competitive ELISA for the detection of antibodies to RVFV in goats and cattle. The recombinant N protein of RVFV was expressed in E. coli with a six-histidine tag, and the purified N protein was used for detecting antigen with a competitive monoclonal antibody against RVFV antib… Show more
“…The diagnostic accuracy estimates determined in our study are similar to those previously published for ELISAs based on a whole RVFV antigen [36][37][38][39][40][41]55] as well as those based on recombinant NP ELISAs [51][52][53][54][55][56][57][58][59][60], including the commercially available NP-based competition ELISAs [52,60]. Although recorded at a relatively low rate, false-positive results were documented in this study across different subpopulations and are of particular concern in ruminants originating from RVF-non-endemic countries.…”
Section: Discussionsupporting
confidence: 87%
“…The inhibition ELISA based on a whole tissue culture-derived, inactivated antigen [ 40 ] and competitive ELISA based on recombinant NP antigen [ 50 , 51 , 52 ] allow multi-species RVFV antibody detection using the same diagnostic procedure without requirements for species-specific conjugates. While in the last 15 years, several groups have developed and evaluated various ELISA formats based on RVFV recombinant NP antigen [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ], more extensive evaluation of their diagnostic performance was only achieved in humans [ 58 ], buffalo [ 59 ], and cattle [ 60 ] to date.…”
Diagnostic performance of an indirect enzyme-linked immunosorbent assay (I-ELISA) based on a recombinant nucleocapsid protein (rNP) of the Rift Valley fever virus (RVFV) was validated for the detection of the IgG antibody in sheep (n = 3367), goat (n = 2632), and cattle (n = 3819) sera. Validation data sets were dichotomized according to the results of a virus neutralization test in sera obtained from RVF-endemic (Burkina Faso, Democratic Republic of Congo, Mozambique, Senegal, Uganda, and Yemen) and RVF-free countries (France, Poland, and the USA). Cut-off values were defined using the two-graph receiver operating characteristic analysis. Estimates of the diagnostic specificity of the RVFV rNP I-ELISA in animals from RVF-endemic countries ranged from 98.6% (cattle) to 99.5% (sheep) while in those originating from RVF-free countries, they ranged from 97.7% (sheep) to 98.1% (goats). Estimates of the diagnostic sensitivity in ruminants from RVF-endemic countries ranged from 90.7% (cattle) to 100% (goats). The results of this large-scale international validation study demonstrate the high diagnostic accuracy of the RVFV rNP I-ELISA. Standard incubation and inactivation procedures evaluated did not have an adverse effect on the detectable levels of the anti-RVFV IgG in ruminant sera and thus, together with recombinant antigen-based I-ELISA, provide a simple, safe, and robust diagnostic platform that can be automated and carried out outside expensive bio-containment facilities. These advantages are particularly important for less-resourced countries where there is a need to accelerate and improve RVF surveillance and research on epidemiology as well as to advance disease control measures.
“…The diagnostic accuracy estimates determined in our study are similar to those previously published for ELISAs based on a whole RVFV antigen [36][37][38][39][40][41]55] as well as those based on recombinant NP ELISAs [51][52][53][54][55][56][57][58][59][60], including the commercially available NP-based competition ELISAs [52,60]. Although recorded at a relatively low rate, false-positive results were documented in this study across different subpopulations and are of particular concern in ruminants originating from RVF-non-endemic countries.…”
Section: Discussionsupporting
confidence: 87%
“…The inhibition ELISA based on a whole tissue culture-derived, inactivated antigen [ 40 ] and competitive ELISA based on recombinant NP antigen [ 50 , 51 , 52 ] allow multi-species RVFV antibody detection using the same diagnostic procedure without requirements for species-specific conjugates. While in the last 15 years, several groups have developed and evaluated various ELISA formats based on RVFV recombinant NP antigen [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ], more extensive evaluation of their diagnostic performance was only achieved in humans [ 58 ], buffalo [ 59 ], and cattle [ 60 ] to date.…”
Diagnostic performance of an indirect enzyme-linked immunosorbent assay (I-ELISA) based on a recombinant nucleocapsid protein (rNP) of the Rift Valley fever virus (RVFV) was validated for the detection of the IgG antibody in sheep (n = 3367), goat (n = 2632), and cattle (n = 3819) sera. Validation data sets were dichotomized according to the results of a virus neutralization test in sera obtained from RVF-endemic (Burkina Faso, Democratic Republic of Congo, Mozambique, Senegal, Uganda, and Yemen) and RVF-free countries (France, Poland, and the USA). Cut-off values were defined using the two-graph receiver operating characteristic analysis. Estimates of the diagnostic specificity of the RVFV rNP I-ELISA in animals from RVF-endemic countries ranged from 98.6% (cattle) to 99.5% (sheep) while in those originating from RVF-free countries, they ranged from 97.7% (sheep) to 98.1% (goats). Estimates of the diagnostic sensitivity in ruminants from RVF-endemic countries ranged from 90.7% (cattle) to 100% (goats). The results of this large-scale international validation study demonstrate the high diagnostic accuracy of the RVFV rNP I-ELISA. Standard incubation and inactivation procedures evaluated did not have an adverse effect on the detectable levels of the anti-RVFV IgG in ruminant sera and thus, together with recombinant antigen-based I-ELISA, provide a simple, safe, and robust diagnostic platform that can be automated and carried out outside expensive bio-containment facilities. These advantages are particularly important for less-resourced countries where there is a need to accelerate and improve RVF surveillance and research on epidemiology as well as to advance disease control measures.
“…Some cross reactions between nucleocapsid protein and IgG antibodies induced by infection with other Simbu serogroup virus members might occur [14]. Limited cross reactions were observed with sera from ruminants experimentally infected with Akabane virus (AKAV) (data not shown).…”
Section: Discussionmentioning
confidence: 96%
“…Using the same strategy developed for Rift valley fever ELISA, the N viral protein of SBV has been expressed in a prokaryote system with a 6 histidine tag [14]. After expression, denaturation in the presence of urea, purification by IMAC chromatography and some desalting steps, the SBV N recombinant protein was used as antigen to discriminate sera from SBV infected from naive animals.…”
A newly developed Enzym Like Immuno Sorbant Assay (ELISA) based on the recombinant nucleocapsid protein (N) of Schmallenberg virus (SBV) was evaluated and validated for the detection of SBV-specific IgG antibodies in ruminant sera by three European Reference Laboratories. Validation data sets derived from sheep, goat and bovine sera collected in France and Germany (n = 1515) in 2011 and 2012 were categorized according to the results of a virus neutralization test (VNT) or an indirect immuno-flurorescence assay (IFA). The specificity was evaluated with 1364 sera from sheep, goat and bovine collected in France and Belgium before 2009. Overall agreement between VNT and ELISA was 98.9% and 98.3% between VNT and IFA, indicating a very good concordance between the different techniques. Although cross-reactions with other Orthobunyavirus from the Simbu serogroup viruses might occur, it is a highly sensitive, specific and robust ELISA-test validated to detect anti-SBV antibodies. This test can be applied for SBV sero-diagnostics and disease-surveillance studies in ruminant species in Europe.
“…VanVuren and Paweska developed an ELISA based on the capture of the nucleocapsid protein (NP) (57). Alternatively, a monoclonal antibody-based competitive ELISA developed by Kim et al for the detected antibodies against RVFV in goats and cattle with a sensitivity/specificity of 94.7/99.7% between 9 and 11 days post-inoculation (58). A multiplex fluorescence microsphere immunoassay (FMIA) also detected cattle and sheep IgM and IgG antibodies to the RVFV glycoprotein, nonstructural proteins, and nucleoprotein (59).…”
Early detection of emerging foreign animal diseases is critical to pathogen surveillance and control programs. Rift valley fever virus (RVFV), Japanese encephalitis virus (JEV), and African swine fever virus (ASFV) represent three taxonomically and ecologically diverse vector-borne viruses with the potential to be introduced to the United States. To promote preparedness for such an event, we reviewed the current surveillance strategies and diagnostic tools in practice around the world for these emerging viruses, and summarized key points pertaining to the availability of existing guidelines and strategic approaches for early detection, surveillance, and disease management activities. We compare and contrast the surveillance and management approaches of these three diverse agents of disease as case studies to emphasize the importance of the ecological context and biology of vectors and vertebrate hosts. The information presented in this review will inform stakeholders of the current state of surveillance approaches against these transboundary foreign animal disease which threaten the United States.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.